Accredited Investors Inc. maintained its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,550 shares of the company’s stock at the end of the second quarter. Accredited Investors Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $284,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 122.4% in the first quarter. Renaissance Technologies LLC now owns 4,817,763 shares of the company’s stock valued at $154,602,000 after buying an additional 2,651,900 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Teva Pharmaceutical Industries Limited by 405,409.9% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,435,505 shares of the company’s stock valued at $46,065,000 after buying an additional 1,435,151 shares in the last quarter. Sei Investments Co. boosted its position in shares of Teva Pharmaceutical Industries Limited by 103.6% in the second quarter. Sei Investments Co. now owns 1,721,466 shares of the company’s stock valued at $57,188,000 after buying an additional 875,789 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Teva Pharmaceutical Industries Limited by 142.2% in the first quarter. Ameriprise Financial Inc. now owns 1,288,571 shares of the company’s stock valued at $41,349,000 after buying an additional 756,441 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI boosted its position in shares of Teva Pharmaceutical Industries Limited by 370.6% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 929,084 shares of the company’s stock valued at $29,814,000 after buying an additional 731,666 shares in the last quarter. 56.27% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.30 on Friday. The company’s 50-day moving average is $29.64 and its 200 day moving average is $31.56. Teva Pharmaceutical Industries Limited has a 12 month low of $16.81 and a 12 month high of $55.39. The company’s market cap is $17.58 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the company earned $1.25 EPS. The company’s revenue was up 12.9% compared to the same quarter last year. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -18.95%.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Stake Held by Accredited Investors Inc.” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/13/teva-pharmaceutical-industries-limited-teva-stake-held-by-accredited-investors-inc.html.

Several equities analysts have recently issued reports on TEVA shares. Zacks Investment Research raised shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, April 17th. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a research note on Monday, July 24th. Deutsche Bank AG lowered their price objective on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, May 12th. Citigroup Inc. lowered their price objective on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, April 25th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $38.00 price objective (down previously from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, May 15th. Three analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.